Cover Image
Market Research Report

Breakthrough Innovations Enhancing Gut Microbial Health

Published by Frost & Sullivan Product code 936664
Published Content info 83 Pages
Delivery time: 1-2 business days
Price
Back to Top
Breakthrough Innovations Enhancing Gut Microbial Health
Published: April 28, 2020 Content info: 83 Pages
Description

Empowering Medical, Academic and Industrial Communities Through Expert Advice Across Multiple Scientific Disciplines

Overall Impact of Breakthrough Innovations in Gut Microbial Health Covered in this Research:

  • Microbiome expertise: Meeting translational research needs from medical, academic and industrial communities through deep diving know-how and expertise across multiple scientific platforms
  • Nutrition and therapeutic fields: Enabling precision medicine and personalized nutrition based on the gut bacteria/human cells interactions in health and disease status
  • Microbiome diagnostics: Discovering new diagnostic/prognostic biomarkers of disease risk and design of novel microbiome modulation strategies
  • Global technology convergence: Digitalizing the human microbiome to derive clinically and pharmacologically meaningful action items from microbiome data
  • Translation to adjacent industries: Driving force for the translation of microbiome discoveries into health-related products and services in food and beverages, flavors and fragrances, cosmetics
Table of Contents
Product Code: D94B

Table of Contents

1.0. Executive Summary

  • 1.1. Research Focus
  • 1.2. Research Scope
  • 1.3. Analysis Framework
  • 1.4. Research Methodology

2.0. Technology Landscape and Trends

  • 2.1. Microbiome Expertise
  • 2.2. Nutrition and Therapeutic Fields
  • 2.3. Microbiome Diagnostics
  • 2.4. Global Technology Convergence
  • 2.5. Translation to Adjacent Industries

3.0. Technology Status Review and Assessment

  • 3.1. Emerging Opportunities for Gut Microbial Health
  • 3.2. Fecal Microbiota Transplantation (FMT)
  • 3.3. Live Biotherapeutic Products (LBPs)
  • 3.4. Small Molecules and Biologics
  • 3.5. Bacteriophages

4.0. Business Landscape and Intellectual Property

  • 4.1. Gut Microbial Health Adoption
  • 4.2. Macro to Micro Vision and Implications
  • 4.3. Summary of Key Industry Drivers
  • 4.4. Summary of Key Industry Challenges
  • 4.5. Summary of Key Market Drivers and Restraints
  • 4.6. Mapping of Key Market Drivers and Restraints
  • 4.7. Technology Transfer Assessment and Perceptions

5.0. Technology Radar and Intelligent Solutions

  • 5.1. Technology Maturity Level and Description
  • 5.2. Roadmap Tapping into Technology Synergy
  • 5.3. Business Model Hybridization
  • 5.4. New Approaches Driving Gut Microbiome Solutions
  • 5.5. Technology Synergy Reshaping Value Chain
  • 5.6. Future Perspectives of Microbiome Technology

6.0. Market Potential and Industry Evolution

  • 6.1. Gut Microbiome: Overall Market Potential
  • 6.2. Gut Microbiome: Market Forecast by Technology
  • 6.3. Gut Microbiome: Market Forecast by Application
  • 6.4. Gut Microbiome: Market Forecast by Product Type
  • 6.5. Gut Microbiome: Market Forecast by Strain Type
  • 6.6. Gut Microbiome: Market Forecast by Species
  • 6.7. Gut Microbiome: Market Forecast by Country/Region
  • 6.8. Gut Microbiome: Market Forecast by Pharmaceutical Segment
  • 6.9. Gut Microbiome: Drug Pipeline Analysis
  • 6.10. Gut Microbiome: Share of Drug Pipeline by Therapeutic Area

7.0. Funding and Investment Landscape

  • 7.1. Funding and Investment Models and Adoption
  • 7.2. Funding Contribution Focus
  • 7.3. Gut Microbial Health Technology Funding Trends
  • 7.4. Funding and Investment Distribution by Type
  • 7.5. Public Funding Distribution by Type
  • 7.6. Public and Private Funding by Region
  • 7.7. Public and Private Funding to Notice

8.0. Industry Dynamics

  • 8.1. Key Future Industry Trends
  • 8.2. Levers for Growth in the Microbiome Space
  • 8.3. Industry Dynamics in the Pharmaceutical Sector
  • 8.4. Regional Adoption Potential for Gut Microbiome Products
  • 8.5. Microbiome Growth Opportunity Assessment
  • 8.6. The Microbiome Industry Ecosystem
  • 8.7. Microbiome-based Cancer Immunotherapies
  • 8.8. Personalized Medicine via Microbiome Companion Diagnostics
  • 8.9. Wellness and Data Monetization Through DTCMT
  • 8.10. Microbiome OTC and Therapeutic Contract Manufacturing

9.0. Companies to Watch

  • 9.1. Disruptive Innovators in Microbiome Platforms
  • 9.2. New Business Opportunities Across the Gut Microbiome Market
  • 9.3. Potential B2B and B2C Partnership Opportunities
  • 9.4. Industry Dynamics Around the Gut Microbiome Space
  • 9.5. Strategic Business Cases in Microbiome Nutrition
  • 9.6. New Product Innovation Opportunities in Microbiome Nutrition
  • 9.7. Key Innovators in Microbiome Technologies
  • 9.8. Key Developers in Microbiome Technologies
  • 9.9. Key Contributors in Microbiome Technologies
  • 9.10. Gut Microbiome Innovators Leading B2B/B2C Opportunities
  • 9.11. Gut Microbiome Companies Engaged in B2B/B2C Opportunities

10.0. Appendix

  • Key Industry Influencers
  • Legal Disclaimer
Back to Top